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Abstract
Background: Understanding stem cell differentiation is essential for the future design of cell
therapies. While retinoic acid (RA) is the most potent small molecule enhancer of skeletal
myogenesis in stem cells, the stage and mechanism of its function has not yet been elucidated.
Further, the intersection of RA with other signalling pathways that stimulate or inhibit myogenesis
(such as Wnt and BMP4, respectively) is unknown. Thus, the purpose of this study is to examine
the molecular mechanisms by which RA enhances skeletal myogenesis and interacts with Wnt and
BMP4 signalling during P19 or mouse embryonic stem (ES) cell differentiation.
Results: Treatment of P19 or mouse ES cells with low levels of RA led to an enhancement of
skeletal myogenesis by upregulating the expression of the mesodermal marker, Wnt3a, the skeletal
muscle progenitor factors Pax3 and Meox1, and the myogenic regulatory factors (MRFs) MyoD and
myogenin. By chromatin immunoprecipitation, RA receptors (RARs) bound directly to regulatory
regions in the Wnt3a, Pax3, and Meox1 genes and RA activated a β-catenin-responsive promoter
in aggregated P19 cells. In the presence of a dominant negative β-catenin/engrailed repressor fusion
protein, RA could not bypass the inhibition of skeletal myogenesis nor upregulate Meox1 or MyoD.
Thus, RA functions both upstream and downstream of Wnt signalling. In contrast, it functions
downstream of BMP4, as it abrogates BMP4 inhibition of myogenesis and Meox1, Pax3, and MyoD
expression. Furthermore, RA downregulated BMP4 expression and upregulated the BMP4
inhibitor, Tob1. Finally, RA inhibited cardiomyogenesis but not in the presence of BMP4.
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Conclusion:  RA can enhance skeletal myogenesis in stem cells at the muscle specification/
progenitor stage by activating RARs bound directly to mesoderm and skeletal muscle progenitor
genes, activating β-catenin function and inhibiting bone morphogenetic protein (BMP) signalling.
Thus, a signalling pathway can function at multiple levels to positively regulate a developmental
program and can function by abrogating inhibitory pathways. Finally, since RA enhances skeletal
muscle progenitor formation, it will be a valuable tool for designing future stem cell therapies.
Background
The initiation of skeletal myogenesis involves a complex
interplay of signalling molecules secreted from the tissues
surrounding the somite, including Wnt, Sonic hedgehog,
and Bone morphogenetic proteins 4 (BMP4) [1-5].
Somites respond to the various signals by activating the
expression of transcription factors that specify cells to the
skeletal muscle lineage, including Pax3, Meox1 and Gli2
[6-10]. Commitment into skeletal myoblasts is dependent
on the expression of the myogenic regulatory factors
(MRFs), including MyoD, Myf-5, myogenin and myf-6/
MRF4/herculin, and is regulated by factors in the dermo-
myotome [11,12].
P19 cells are pluripotent embryonal carcinoma (EC) cells,
derived from mouse embryonic stem (ES) cells, that can
differentiate into cardiac and skeletal muscle in a dimeth-
ylsulfoxide (DMSO)- and aggregation-dependent manner
[13]. While cells grown in monolayer maintain their stem
cell phenotype, the process of cellular aggregation initi-
ates mesoderm induction, shown by the expression of
Brachyury T [14]. Subsequent muscle development pro-
ceeds in the presence of DMSO. The order of transcription
factors and signalling pathways for myogenesis in P19
cells appear to be similar to those during early embryo-
genesis. Thus P19 cells are a useful tool for examining in
vitro  myogenesis, potentially leading to novel mecha-
nisms relevant to ES stem cell therapy.
Retinoic acid (RA) is a derivative of vitamin A and plays a
crucial role in a wide variety of embryonic developmental
processes [15]. In the embryo, the ability of RA to bind its
receptors (retinoic acid receptors [RARs]/retinoid × recep-
tors [RXRs]) is precisely controlled by regulating the avail-
ability of RA through proteins that synthesize RA, such as
retinaldehyde dehydrogenase 2 (RALDH2), and those
that metabolize RA, such as Cyp26, and other proteins
that transport or bind RA.
Low levels of RA are known to enhance skeletal myogene-
sis in stem cells and myoblast cell lines [16-18]. RA can
regulate MRF expression in myoblasts and chick limb [17-
19], whereas RARs interact and synergize with MRFs [20].
However, the exact stage(s) at which RA functions to
enhance skeletal myogenesis in a stem cell context has not
been clearly defined.
Altered RA signalling in vertebrates affects body pattern-
ing, generating homeotic transformations and/or segmen-
tation defects [21]. In Xenopus  embryos, RA signalling
regulates segmental patterning by promoting anterior seg-
mental polarity and by positioning segmental boundaries
[22]. In mice, RA coordinates somitogenesis and left-right
patterning [23]. How the effect of RA on the somite
impacts on the development of the myotome is not well
understood.
In the canonical pathway, Wnt binds to cell surface recep-
tors of the frizzled family, leading to the activation of
Dishevelled and stabilization of cytosolic β-catenin [24].
In a simplified view, β-catenin enters the nucleus, binds
the T-cell factor/lymphoid enhancer factor (TCF/LEF)
family of transcription factors, and activates gene expres-
sion. Several studies have shown that exogenous Wnt and/
or activated β-catenin can replace the dorsal neural tube in
the induction of myogenesis in somite explant cultures
[25]. A combination of Wnt and Shh signals regulates the
expression levels of both β-catenin and Lef1 in the myo-
tome prior to MyoD expression in the chick [26]. Further,
β-catenin regulates the expression of Pax3 [27]. In P19
cells, a dominant negative β-catenin inhibits the expres-
sion of Pax3, Gli2, Meox1, MyoD, and abrogates myogen-
esis [8]. Finally, Wnt was shown to act directly on the
Myf5 epaxial enhancer via β-catenin [28]. Therefore, there
is strong evidence that Wnt signalling regulates specifica-
tion and commitment into the skeletal muscle lineage.
How Wnt signalling intersects with RA signalling during
myogenesis is unknown.
BMP4 belongs to the TGF-β superfamily of peptide
growth factors [29]. BMPs inhibit myogenesis in myoblast
cell lines, limb micromass cultures, and developing
somites [3,30,31]. Noggin signals are derived from the
notochord and the somite. Noggin signalling is believed
to counteract the inhibitory effects of BMP4 on the epaxial
somite [32-34]. Further experiments using somite
explants showed that relative levels of BMP4 and noggin
regulated the activity of Pax3 to control the temporal and
spatial activation of the MRFs [35]. Therefore, extensive
studies have demonstrated the inhibition of embryonic
skeletal myogenesis by BMP. How BMP signalling inter-
sects with RA signalling is unknown.BMC Biology 2009, 7:67 http://www.biomedcentral.com/1741-7007/7/67
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The role of BMP in cardiomyogenesis has also been exten-
sively studied. In Drosophila, the BMP homologue decap-
entaplegic protein (dpp) is secreted from the dorsal
ectoderm and maintains tinman expression in the meso-
derm [36]. Similarly, in chick BMP2 or -4 is expressed in
tissues adjacent to the precardiac mesoderm and can
induce Nkx2-5 and GATA-4 expression [37,38]. Con-
versely, disruption of BMP signalling with noggin or dom-
inant negative receptors can prevent cardiomyogenesis in
chick,  Xenopus, ES, P19 and P19CL6 cells [37,39-45].
Therefore, BMP/dpp signalling is essential in controlling
cardiomyogenesis.
Studies with embryonic stem and embryonic carcinoma
cells have shown that RA inhibits cardiomyogenesis when
added at an early stage [16,46,47] and enhances ES cell
cardiomyogenesis when added at a late stage of differenti-
ation [46,48]. RA can block myocardial gene expression,
including XNkx2.5, in Xenopus embryos [49] and can alter
cardiomyogenesis proliferation and patterning in other
model systems [50-53]. Mice lacking various combina-
tions of RXRs and RARs have shown that retinoids are
required to prevent differentiation and support prolifera-
tion of ventricular cardiomyocytes [54,55]. RA deficiency
in RALDH2 -/- mice alters second heart field formation
[56,57]. Clearly, RA affects the timing and positioning of
cardiomyogenesis at multiple levels and further studies
are required to dissect out the role of RA at each step of
development.
Here we investigate signalling events leading to the con-
trol of stem cell entry into skeletal and cardiac muscle lin-
eages by RA, Wnt, and BMP4. We show that low levels of
RA stimulate skeletal myogenesis by accelerating and
increasing the expression of Wnt3a, Pax3, Meox1, and
MRFs. This early and enhanced activation of skeletal mus-
cle is refractory to inhibitory signals from BMP4 but not
from a dominant negative β-catenin. Furthermore, low
levels of RA inhibit stem cell differentiation into the car-
diac muscle lineage, as shown by the absence of GATA-4
expression. The inhibitory activity of RA on cardiomyo-
genesis can be abrogated by the presence of BMP4. There-
fore, BMP4 and RA function antagonistically to regulate
each other's inhibition of entry into skeletal and cardiac
muscle lineages, respectively. However, RA functions both
upstream and downstream of Wnt signalling through β-
catenin.
Results
RA inhibits cardiomyogenesis and enhances entry into the 
skeletal muscle lineage in P19 cells
Previous studies have shown that RA can inhibit cardio-
myogenesis and enhance skeletal myogenesis [16,47], but
the stage at which this occurs and the interaction with
other signalling pathways have not been clearly defined.
To investigate the mechanisms by which RA modulates
myogenesis in P19 cells, various concentrations of RA, in
the presence of DMSO, were examined. In agreement with
previous results [47], it was found that skeletal myogene-
sis occurred in the presence of DMSO but not in its
absence (summarized in Table 1). Furthermore, 3-30 nM
of RA with DMSO was sufficient to block cardiac and
enhance skeletal muscle development (data not shown).
A time course of P19 cell differentiation was carried out in
the presence of DMSO, with and without 30 nM of RA.
Cells were fixed on day 9 for immunofluorescence and
stained with an anti-myosin heavy chain (MyHC) anti-
body, MF20, which identifies MyHC in both cardiac and
skeletal myocytes. Cardiac and skeletal myocytes can be
distinguished by their morphology and time of appear-
ance, with rounded cardiac myocytes appearing by day 6
and elongated, bipolar skeletal myocytes by day 9 [13].
Cells treated with RA did not differentiate into cardiac
muscle, evidenced by the absence of rounded cardiac
myocytes, expressing MyHC, compared to cells not treated
with RA (Figure 1, panels IB and D). In contrast, signifi-
cantly enhanced levels of bipolar skeletal myocytes were
observed in the presence compared to the absence of RA
(Figure 1, panels IA and C). Quantification of the number
of cardiac and skeletal myocytes after treatment with RA
showed that the fourfold increase in skeletal myocytes
and eightfold loss of cardiac myocytes were statistically
significant (Figure 1, panel II). Therefore, in agreement
with others [58], RA inhibited cardiomyogenesis and
enhanced skeletal myogenesis in P19 cells.
In order to examine the molecular basis of the effects of
RA on myogenesis, total RNA was harvested from a time
course of cells differentiated with and without RA and
subjected to northern blot analysis. Endogenous RALDH2
levels were enhanced on day 2 of the DMSO-induced dif-
ferentiation in the absence of exogenous RA (Figure 1,
panel IIIA), indicating that endogenous RA signalling
could be involved at this stage of development [59]. RA-
treated cells showed enhanced expression of RALDH2
from days 3-5 (Figure 1, panel IIIA). To determine at what
stage cardiomyogenesis was inhibited by RA, expression
of the cardiomyoblast gene GATA-4, was examined [60].
Northern blot analysis revealed a lack of induction of
GATA-4 transcripts in cells treated with RA (Figure 1,
panel IIIB), consistent with the interpretation that under
these conditions RA inhibits commitment into the cardiac
muscle lineage.
In order to determine at which stage skeletal myogenesis
was enhanced, the expression of genes expressed in the
primitive streak (Brachyury T and Wnt3a), the dermo-
myotome (Pax3 and Meox1), and skeletal myoblasts
(MyoD and myogenin) was examined. Mesoderm induc-
tion occurred in the presence of RA, shown by the expres-
sion of Brachyury T (Figure 1, panel IIIC). The levels of
Brachyury T appear to be slightly decreased with RA, con-BMC Biology 2009, 7:67 http://www.biomedcentral.com/1741-7007/7/67
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sistent with the increasing differentiation of mesodermal
progenitors. In contrast to the results with GATA-4 expres-
sion, Wnt3a (days 4-6), Pax3 (days 2-9), Meox1 (days 3-
4), MyoD (days 6-9) and Myogenin (days 6-9) transcripts
were upregulated with RA treatment (Figure 1, panels
IIID-H), which is consistent with an increase in skeletal
myogenesis. Quantitative polymerase chain reaction (Q-
PCR) was used to quantify the levels of Pax3, MyoD and
Wnt3a transcripts, showing a 9-95-fold upregulation of
these factors with RA treatment (Figure 1, panel IV).
Hence, RA enhances skeletal myogenesis by upregulating
Wnt3a, Pax3 and Meox1 (summarized in Table 1).
Since BMP4 is known to inhibit skeletal and enhance car-
diac myogenesis [61], and RA has been shown to inhibit
BMP4 expression in the limb forebud [62], we examined
the expression of BMP4 transcripts in the presence and
absence of RA (Figure 1, panel III- I). The endogenous lev-
els of BMP4 were down-regulated in RA-treated cells rela-
tive to the controls from days 3-9. Finally, we examined
the expression of the transducer of ErbB2 (Tob1), an
intrinsic inhibitor of BMP signalling [63,64]. Tob1 was
upregulated by RA from days 2-9 (Figure 1, panel III-J).
Thus, RA may function to enhance skeletal myogenesis
and inhibit cardiomyogenesis in part by inhibiting BMP4
expression and/or function.
To identify direct chromatin targets of RAR binding, we
used multiple sequence local alignment and visualization
http://mulan.dcode.org/ to find RA response elements
(RARE) sequences (defined as two tandem repeats of the
RGKTCA element in DR1-7 arrangements) located within
+/- 100 Kb of the start site for Wnt3a, Pax3 and Meox1.
While all three genes contained RARE sequences, only one
of the two Meox1 sites (Meox1-2) and one of the two Pax3
sites (Pax3-2) were conserved between mouse and
human, located in Mus musculus at -33869 bp and +
114735, respectively (Figure 1, panel VI). Chromatin
immunoprecipitation experiments were performed on
day 2 of differentiation, using an antibody that recognizes
all RARs. We detected a significant 3.6-fold enrichment in
chromatin fragments corresponding to the Meox1-2 site,
and a significant 2.3-fold enrichment in chromatin frag-
ments corresponding to the Pax3-2 site compared to
immunoprecipitation with a rabbit IgG as a negative con-
trol (Figure 1, panel V). We also tested several of the non-
conserved RAREs identified upstream of Wnt3a. One of
these RAREs (Wnt3a-2 at position -36625) showed a sig-
nificant 1.9-fold enrichment. Several non-conserved
RARE sequences in Wnt3a, Meox1, or Pax3 genes were not
significantly associated with immunoprecipitated RARs,
whereas a known site in RARβ2 was associated, as
expected [65]. Thus, RARs bind to conserved elements in
the Meox1 and Pax3 genes as well as to one non-con-
Table 1: Summary of gene expression changes in cell lines treated with and without DMSO and/or RA.
Cardiac Skeletal Markers
Cell line Conditions GATA-4  Pax3 Gli2 Meox1 MRFs Figure
P19 - - - - - - Fig. 7 & Data not shown
P19 +DMSO + + + + + Figs. 1 & 4
P19 +DMSO&RA - +++ + +++ +++ Figs. 1 & 4
P19 [β-cat/EnR] +DMSO N.D. - - - - Figs. 3 & 4
P19 [β-cat/EnR] +DMSO&RA N.D. +++ +++ - - Figs. 3 & 4
P19 [BMP] - - - - - - Data not shown
P19 [BMP] +DMSO + - N.D. - - Fig. 6, 7 & 8
P19 [BMP] +DMSO&RA + +++ N.D. N.D. +++ Fig. 8
Mouse ES - + - N.D. +/- - Fig. 2
Mouse ES +RA +/- +++ N.D. +++ +++ Fig. 2
P19 cell lines indicated on the right were aggregated under the conditions described and the induction of muscle marker gene expression was 
monitored.
(+++ = high expression; + = normal expression; +/- = partial expression, - = not expressed; N.D. = not determined)BMC Biology 2009, 7:67 http://www.biomedcentral.com/1741-7007/7/67
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Retinoic acid inhibits cardiomyogenesis and enhances skeletal myogenesis in P19 cells Figure 1
Retinoic acid inhibits cardiomyogenesis and enhances skeletal myogenesis in P19 cells. P19 cells were aggregated 
with 0.8% dimethylsulfoxide (DMSO) in the presence and absence of 30 nM RA. Panel I: Cells were fixed on day 9 for immun-
ofluorescence with MF20 antibody (A-D) and counter stained with Hoechst dye (E-H). Magnification is 160x. Panel II: Cardiac 
(n = 3) and skeletal (n = 4) myogenesis were quantified by counting the number of MHC+ve myocytes as a percentage of the 
total. Average +/- standard error of mean (SEM) is shown and statistics were Student's t-test, *P < 0.05. Panel III: Total RNA 
was harvested for northern blot analysis on the days indicated and hybridized to the cDNAs on the right. Lanes are spliced 
from the same autoradiogram. Panel IV: Quantitative polymerase chain reaction (PCR) analysis was performed on day 4 of dif-
ferentiation for Pax3 and Wnt3a transcript levels (n = 2) and on day 9 for MyoD levels (n = 4). Results were expressed as fold 
change of transcript levels in the presence compared to the absence of RA treatment. Panel V: Chromatin immunoprecipitation 
experiments were performed on day 2 P19 aggregates treated with DMSO/retinoic acid and analysed by real-time PCR using 
primers for sites within regulatory regions of the genes indicated. Average +/-SEM is shown, relative to IgG, and statistics were 
Student's t-test of each region compared to IgG, n = 3-4, *P < 0.05. Panel VI: The position and conservation of the Meox1-2 and 
the Pax3-2 retinoic acid response elements are shown.
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served element upstream of Wnt3a in a population of dif-
ferentiating P19 cells, indicating that RA functions both
upstream and downstream of Wnt3a signalling.
RA enhances skeletal myogenesis in mES cells
To determine if our results in P19 cells were applicable to
mouse embryonic stem (mES) cells, we differentiated
mES cells in hanging drops for 2 days and in suspension
culture for an additional 5 days, the latter with 0-50 nM
RA. After re-plating in tissue culture dishes, cells were har-
vested on days 7 and 15 for RNA and fixed on day 20 for
immunofluorescence. Examination of RNA by RT-PCR
indicated increasing transcript levels of Meox1, Pax3, and
MyoD in the presence of retinoic acid, peaking at 25 nM
(Figure 2, panel I). Quantification of gene expression
changes by Q-PCR indicated statistically significant 20-
fold increases in Pax3 and Meox1 expression on day 7 and
a significant fivefold increase in myogenin on day 15 (Fig-
ure 2, panel II). Finally, skeletal myocytes were not
observed on day 20 in the absence of RA, as shown by the
lack of bipolar cells reacting with MF20 (Figure 2, panel
III-B). In the presence of 25 nM RA, MyHC+ve bipolar skel-
etal myocytes were visible (Figure 2, panel IIID). Thus,
similar to the findings in P19 cells, RA treatment of mES
cells results in the enhancement of skeletal muscle pro-
genitor formation, shown by the increase in expression of
Pax3, Meox1, MyoD, and myogenin (summarized in
Table 1).
RA cannot bypass the inhibition of skeletal myogenesis by 
a dominant negative β-catenin
Since earlier studies have shown that Wnt signalling, via
β-catenin, activates Pax3, Gli2 and Meox1 expression,
inducing skeletal myogenesis in P19 cells [8], we were
interested in determining how the Wnt signalling path-
way intersects with RA signalling. Furthermore, a domi-
nant negative β-catenin, with the transcriptional
activation domain replaced by an engrailed repressor
domain (β-Cat/EnR), inhibited skeletal myogenesis in
P19 cells [8]. This dominant negative approach identifies
genes bound by β-catenin and their downstream targets.
In order to determine if RA can bypass this inhibition, P19
cells expressing β-Cat/EnR were differentiated in the pres-
ence of DMSO, with and without RA and compared to
control P19 cells. Cultures were fixed on day 9 and exam-
ined by immunofluorescence with MF20. In agreement
with previous results [8], the overexpression of β-Cat/EnR
resulted in the loss of skeletal myogenesis, shown by the
lack of bipolar skeletal myocytes, compared to control
cells (Figure 3D versus B). The addition of RA resulted in
an increase in the number of skeletal myocytes observed
in control cells (Figure 3F versus B), but not in P19 [β-Cat/
EnR] cells (Figure 3H). Therefore, RA was not sufficient to
circumvent the inhibition of skeletal myogenesis by β-
Cat/EnR.
To examine at which time point the RA enhancement of
skeletal myogenesis was inhibited by β-Cat/EnR, RNA was
harvested on days 0, 5 and 9 from P19 [control] and P19
[β-Cat/EnR] cultures differentiated with increasing
amounts of RA. Northern blots showed the expression of
exogenous β-Cat/EnR in the P19 [β-Cat/EnR] cells and not
in P19 [control] cells (Figure 4, panel IA). Endogenous β-
Catenin expression was constitutive, as expected (Figure 4,
panel IB). In agreement with Figure 1, MyoD, Meox1 and
Pax3 were upregulated with 3 and 10 nM RA in P19 [con-
trol] cells, compared to no RA treatment (Figure 4, panels
IC - E, lanes 4-7 versus lanes 2-3). Gli2 was upregulated
during myogenesis on days 5 and 9, in agreement with
previous results [9], but was not further upregulated by RA
(Figure 4, panel IF). Interestingly, while MyoD and Meox1
were no longer upregulated by RA in the presence of β-
Cat/EnR (Figure 4, panels IC - D, lanes 11-14), Pax3 tran-
script levels were increased by RA treatment (Figure 4,
panel IE, lanes 11-14). Myogenin and Myf-5 were also not
upregulated in P19 [β-Cat/EnR] cells treated with RA (data
not shown). The enhancement of Gli2 during myogenesis
(Figure 4, panel IF, lanes 2-3) was abrogated in the pres-
ence of β-Cat/EnR (lanes 9-10), as shown previously [8].
This loss of Gli2 expression was reversed in the presence
of RA (Figure 4, panel IF, lanes 11-14). Therefore, the RA
enhancement of MyoD and Meox1 was abrogated in the
presence of β-Cat/EnR, but not the enhancement of Pax3.
Furthermore, the Gli2 expression became responsive to
RA in the presence of β-Cat/EnR (summarized in Table 1).
Changes in gene expression for Pax3 and Pax7 were quan-
tified by Q-PCR (Figure 4, panel II). RA treatment resulted
in the increased expression of Pax3 and Pax7 in P19 [β-
Cat/EnR] cells on days 5 and 9 (Figure 4, panel II). Thus,
both Pax3 and Pax7 were upregulated by RA in the pres-
ence of β-Cat/EnR.
To further assess the relationship between RA and Wnt,
the ability of RA to activate a β-catenin-responsive pro-
moter - TOPflash - which contains 8 high mobility group
(HMG) box sites, was examined using luciferase assays
and compared to a mutated HMG box promoter, FOP-
flash [66]. Both 10 and 100 nM RA were sufficient to
induce four- to fivefold increases in β-catenin activity in
aggregated P19 cells (Figure 4, panel III). Interestingly, the
activation by RA required cellular aggregation, since RA
did not significantly enhance β-catenin function in mon-
olayer cultures. Furthermore, no evidence was obtained of
synergy or inhibition of RARβ on β-catenin activity using
a  β-catenin-responsive TOPflash reporter (data not
shown), in contrast to previous reports of inhibition [67].
Thus RA can activate β-catenin function in DMSO-treated
P19 aggregates, likely by enhancing β-catenin transloca-
tion to the nucleus.BMC Biology 2009, 7:67 http://www.biomedcentral.com/1741-7007/7/67
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Mouse embryonic stem (mES) cells differentiate into skeletal muscle in response to retinoic acid (RA) Figure 2
Mouse embryonic stem (mES) cells differentiate into skeletal muscle in response to retinoic acid (RA). mES 
cells were aggregated in hanging drops for 2 days, cultured in suspension for a further 5 days with increasing concentrations of 
RA, and transferred to tissue culture dishes. Panel I: RNA was harvested from day 7 cultures and subjected to reverse tran-
scriptase- polymerase chain reaction (PCR) followed by Southern blot analysis with the probes indicated on the left. Panel II: 
RNA was harvested from days 7 and 15 after differentiation with or without 25nM retinoic acid and examined by quantitative 
PCR analysis. The expression levels are expressed as fold increase in the presence, compared to the absence of RA, as the 
mean and standard error, n = 3. Statistics were Student's t-test, *P < 0.05. Panel III: On day 20 of differentiation, cells were fixed 
and reacted with Hoechst dye to detect nuclei (A and C) and with MF20 antibody to detect muscle (B and D). Magnification is 
400×.
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Retinoic acid (RA) cannot override the inhibition of skeletal myogenesis by β-Cat/EnR Figure 3
Retinoic acid (RA) cannot override the inhibition of skeletal myogenesis by β-Cat/EnR. P19[control] (A, B, E, F) 
and P19[β-Cat/EnR] (C, D, G, H) cells were aggregated in the presence of 0.8% dimethylsulfoxide (DMSO) with (E-H) and 
without (A-D) 10 nM RA. Cells were fixed on day 9 of differentiation for immunofluorescence with MF20 antibody (B, D, F, H) 
and counter stained with Hoechst dye (A, C, E, G). Magnification is 160×.
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Retinoic acid (RA) enhances the expression of Pax3/7 but not MyoD or Meox1 in the presence of β-Cat/EnR Figure 4
Retinoic acid (RA) enhances the expression of Pax3/7 but not MyoD or Meox1 in the presence of β-Cat/EnR. 
Panel I: P19[control] and P19[β-Cat/EnR] cultures were differentiated with 0.8% dimethylsulfoxide in the presence of 0, 3, and 
10 nM RA. Total RNA was harvested and hybridized with the probes as indicated. Panel II: quantitative polymerase chain reac-
tion analysis of Pax3 and Pax7 transcript levels, for each condition in Panel I, shown as one representative experiment per-
formed in triplicate. Panel III: RA activates β-catenin in P19 aggregate but not monolayer cultures. P19 cells were transfected 
with the TOPFlash or FOPFlash reporter and treated with the compounds indicated in aggregated or monolayer cultures. Cells 
were harvested 24 hours later for luciferase assays (n = 2). Numbers represent the average +/- standard error of mean and sta-
tistics were Student's t-test, *P < 0.05.
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Induction of Pax3 by RA is not due to enhanced 
neurogenesis
Since high levels of RA (1 μM) can induce neurogenesis in
P19 cells and both Pax3 and Shh signalling via Gli2 can
regulate neurogenesis in spinal cord and brain [68-70],
the increase in Pax3 mRNA may not reflect skeletal myo-
genesis but, rather, result from an increase in neurogene-
sis. To test this hypothesis, we quantified the percentage of
cells that differentiated to a neuronal phenotype in P19
[control] and P19 [β-Cat/EnR] cells under cardiac and
skeletal myogenic conditions (1%DMSO), skeletal myo-
genic conditions (1%DMSO+10 nM RA), or neurogenic
conditions (1%DMSO+ 1 μM RA) (Figure 5). Differentia-
tion to a post-mitotic neuronal phenotype was identified
by labelling of neuron-specific β-III tubulin using anti-
Tuj1 antibodies. As expected, 1 μM RA triggered a signifi-
cant neuronal differentiation compared to DMSO alone
(Figure 5, panels I and III). However, neurogenesis with
10 nM RA was variable and was not significantly different
compared to DMSO alone (Figure 5, panels I and III).
Consistent with previous reports that the dominant-nega-
tive inhibition of β-catenin signalling reduces neurogene-
sis [71], we found that significantly fewer cells
differentiated to Tuj1-positive neurons in P19 [β-Cat/
EnR] cultures treated with 1 μM RA (Figure 5, panels II
and III).
In order to determine whether Pax3/7 proteins were
found in neurons, or in neural precursor cells, we used
immunofluorescence to co-localize Pax3/7 proteins with
neuronal markers (Figure 5, panels IV and V). Anti-Tuj1
antibodies were used to detect immature neurons and
anti-double cortin (DCX) antibodies were used to detect
committed neuronal precursor cells. DCX protein is
expressed as early as 1 day after the initiation of neurogen-
esis in P19 cells and is the earliest known marker of neu-
rogenesis [72]. To confirm that P19 cells do not express
Pax3/7 following neuronal commitment, we quantified
the percentage of Pax3/7-positive neuronal precursors
and immature neurons in our day 9 cultures (Figure 5,
panels IV and V). Under all conditions tested, the over-
whelming majority of Pax3/7-positive cells were non-neu-
ronal (Figure 5, panels IV and V). No Pax3/7-positive
neurons were detected in P19 [control] cultures under
conditions promoting skeletal myogenesis (DMSO + 10
nM RA) (Figure 5, panels IV and V). Taken together, these
results provide strong evidence that enhancement of Pax3
and Gli2 expression by low concentrations of RA is indic-
ative of increased skeletal myogenesis and not neurogen-
esis.
Overexpression of BMP4 blocks skeletal myogenesis in P19 
cells
Since RA enhances skeletal myogenesis, while downregu-
lating BMP4 expression, we were interested in examining
the interplay between RA and BMP4 in P19 cell myogene-
sis. In order to examine the effect of BMP4 on skeletal
myogenesis in a stem cell context, stable cell lines express-
ing BMP4 were isolated and termed P19 [BMP4] cells.
When aggregated in the absence of DMSO and examined
for immunofluorescence with MF20, neither skeletal nor
cardiac myogenesis occurred in P19 [BMP4] cells (data
not shown). When cells were aggregated in the presence of
DMSO, P19 [BMP4] cells differentiated into cardiac mus-
cle (Figure 6, panel IA) but not skeletal muscle (Figure 6,
panel IB). Under these conditions, control cells differenti-
ated efficiently into both cardiac (Figure 6, panel IC) and
skeletal muscle (Figure 6, panel ID). Furthermore, a simi-
lar inhibition of skeletal myogenesis was obtained when
parental P19 cells were mixed with P19 [BMP4] cells in
various ratios and aggregated in the presence of DMSO
(data not shown). This indicated that BMP4 can function
extracellularly. By counting the number of MHC+ve cells,
skeletal myogenesis was inhibited an average of approxi-
mately fivefold in the presence of BMP4 and cardiomyo-
genesis was enhanced about 1.6-fold (Figure 6, panel II).
Thus, overexpression of BMP4 in P19 cells is sufficient to
block skeletal muscle and to slightly enhance cardiac mus-
cle development.
BMP4 inhibits skeletal muscle specification
In order to investigate at what point in the pathway BMP4
inhibited myogenesis, the expression patterns of skeletal
muscle-specific markers in P19 [BMP4] and P19 [control]
cells during DMSO-induced differentiation were com-
pared. Total RNA was harvested on days 0, 6 and 9 for
northern blot analysis. P19 [BMP4] cell lines expressed
high levels of BMP4 (Figure 7, panel IA), but failed to
express early markers of skeletal myogenesis such as
Meox1 and Pax3 (Figure 7, panels IB - C) and late markers
such as MyoD (Figure 7, panel ID) compared to P19 [con-
trol] cells. A 17-fold loss of MyoD transcript levels was
detected by Q-PCR in the presence of BMP4 (Figure 8,
panel II). These findings suggest that BMP4 inhibited an
early stage of skeletal muscle development by preventing
proper muscle specification (summarized in Table 1).
To determine if mesoderm induction, the stage prior to
muscle specification, was affected by BMP4 expression, a
time course of DMSO-induced differentiation was per-
formed. P19 [BMP4] and P19 [control] cells were aggre-
gated in the presence of DMSO and total RNA was
harvested during the time course of differentiation for
northern blot analysis. P19 [BMP4] and P19 [control] cell
lines both expressed the mesoderm markers BrachyuryT
and Wnt5b (Figure 7, panels IIA and B). Wnt5b expres-
sion levels appeared to be slightly increased. Finally, in
order to compare the abilities of RA and BMP4 to enhance
β-catenin activity, P19 cells were aggregated with DMSO
in the presence and absence of BMP4 and the β-catenin-
responsive TOPflash promoter was examined by luci-
ferase assay. BMP4 was able to activate the β-catenin-BMC Biology 2009, 7:67 http://www.biomedcentral.com/1741-7007/7/67
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PAX3/7 expression in P19 cultures treated with dimethylsulfoxide (DMSO) and 10 nM retinoic acid (RA) is indicative of skele- tal myogenesis and not neurogenesis Figure 5
PAX3/7 expression in P19 cultures treated with dimethylsulfoxide (DMSO) and 10 nM retinoic acid (RA) is 
indicative of skeletal myogenesis and not neurogenesis. Panel I: P19[control] cells, undifferentiated in monolayer cul-
tures (control) or differentiated with 1% DMSO, 1% DMSO+ 10 nM RA, or 1% DMSO + 1 μM RA for 9 days, were immunola-
belled with anti-TuJ1 (green) to detect terminally differentiated neurons and stained with the nuclear marker Hoechst (blue). 
Panel II: P19[β-Cat/EnR] cells were treated as in Panel I. Panel III: Quantitative analysis of the percentage of Tuj1-positive cells 
was established, expressed as the percentage of the total cell number (n = 6-10). Panel IV: Immunofluorescent staining of PAX3/
7 protein (green), committed neuronal precursors (doublecortin-positive, red), and terminally differentiated neurons (TuJ1-
positive, blue) in triple-labelled P19[control] cultures treated with DMSO + 10 nM RA, demonstrating that PAX3/7-positive 
cells (arrow) are not neuronal precursors or neurons. Panel V: Quantitative analysis indicated that the overwhelming majority 
of PAX3/7-positive cells in all treatments were non-neuronal. Statistics were analysis of variance, post-hoc Bonferroni, *P < 
0.05, Scale bars, 50 μm.BMC Biology 2009, 7:67 http://www.biomedcentral.com/1741-7007/7/67
Page 12 of 21
(page number not for citation purposes)
BMP4 inhibits skeletal but not cardiac myogenesis Figure 6
BMP4 inhibits skeletal but not cardiac myogenesis. Panel I: P19[BMP4] and P19[control] cells were aggregated in the 
presence of 0.8% dimethylsulfoxide (DMSO). Cells were fixed on day 9, stained with MF20 antibody (A-D), and counter-
stained with Hoechst dye to show the nuclei (E-H). Magnification is 400x. Panel II: The number of MHC+ve cells were counted 
and the average +/- standard error of mean shown. Statistics were Student's t-test, *P < 0.05, n = 3.
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responsive reporter in aggregated P19 cells treated with
DMSO (Figure 7, panel III). Taken together, these results
show that BMP4 interfered with skeletal myogenesis at a
time point after mesoderm induction but before the spec-
ification of skeletal muscle.
Reciprocal regulation of myogenesis by RA and BMP4
Since BMP4 was found to inhibit, and RA to enhance skel-
etal muscle specification in P19 cells, we wanted to deter-
mine if BMP4 could override the enhancement of skeletal
myogenesis by RA, and vice versa for cardiomyogenesis.
To this end, P19 cells were mixed with P19 [BMP4] or P19
[control] cells and aggregated in the presence of DMSO
with or without RA. As expected, P19 cells, mixed with
P19 [control] cells and aggregated in the presence of
DMSO, differentiated readily into cardiac and skeletal
muscle, as seen by positive MyHC staining. As shown in
Figures 1 and 4, and quantified in Figure 8, RA inhibited
cardiac myogenesis (3.6-fold), but not skeletal myogene-
sis, and BMP4 inhibited skeletal myogenesis (5.5-fold),
but not cardiac myogenesis (Figure 8, panels II and III).
However, P19 cells mixed with P19 [BMP4] cells and
treated with RA differentiated efficiently into both cardiac
and skeletal muscle (Figure 8, panels I-III), indicating that
RA and BMP4 could antagonize each other's inhibitory
activities.
The results of immunofluorescence were confirmed by
RNA analysis. Cultures of P19 cells mixed with P19
[BMP4] cell lines contained high levels of BMP4 tran-
scripts on days 6 and 9 (Figure 8, panel IVA, lanes 2-9).
GATA-4 transcripts were present in cultures containing
both BMP4 and RA, indicating that BMP4 abrogated the
inhibition of cardiomyogenesis by RA (Figure 8, panel
IVB, lanes 6-9). MyoD and myosin light chain1/3 (MLC1/
3) transcripts were absent in P19 [BMP4], compared to
P19 [control] cells (Figure 8, panel IVC - D, lanes 2-5 com-
pared to 1). In contrast, P19 cells treated with BMP4 and
RA robustly expressed MyoD and MLC1/3 transcripts (Fig-
ure 8, panels IVC and D, lanes 7 and 9). Quantification of
MyoD transcript levels under the four conditions by Q-
PCR was consistent with the results from counting skeletal
myocytes (Figure 8, panel II). Therefore RA enhanced skel-
etal myogenesis and antagonized the inhibitory actions of
BMP4 signalling.
Based on the inability of BMP4 to inhibit skeletal muscle
development in the presence of RA, we predicted that the
accelerated expression of Pax3 with RA treatment would
still be observed in the presence of BMP4. To test this, we
examined a time course of P19 cell differentiation in the
presence of P19 [BMP4] cells and RA. Total RNA was har-
vested on days 1-4, 6, and 9 for northern blot analysis.
Exogenous BMP4 transcripts were present in P19 [BMP4]
BMP4 inhibits skeletal muscle specification Figure 7
BMP4 inhibits skeletal muscle specification. Panels I 
and II: P19[BMP4] and P19[control] cells were aggregated in 
the presence of 0.8% dimethylsulfoxide (DMSO). P19[con-
trol] cells were also aggregated in the absence of DMSO to 
serve as negative controls. On days 0, 6 and 9 (Panel I) and 
days 1-5 (Panel II), total RNA was harvested for northern 
blot analysis and hybridized with the cDNAs indicated on the 
right. Panel III: P19 cells were transfected with the TOPFlash 
reporter, aggregated, and treated with the compounds indi-
cated. Cells were harvested 24 hours later for luciferase 
assays (n = 2). Numbers represent the average +/- standard 
error of mean and statistics were Student's t-test, *P < 0.05.
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Retinoic acid (RA) and BMP4 counteract each other's inhibition of skeletal myogenesis or cardiomyogenesis Figure 8
Retinoic acid (RA) and BMP4 counteract each other's inhibition of skeletal myogenesis or cardiomyogenesis. 
P19 cells were mixed with P19[BMP4] or P19[control] cells in the presence of 1% dimethylsulfoxide (DMSO), with or without 
RA. Panel I: P19[BMP4] cultures treated with RA were fixed on day 9 for immunofluorescence with MF20 antibody (A, B) and 
counter stained with Hoechst dye (C, D). Magnification is 160x. Panel II: Skeletal myogenesis was quantified for each condition 
by counting the number of myosin heavy chain+ve bipolar skeletal myocytes, expressed as the percentage of total cells (white 
bars) and their standard errors (n = 3). MyoD transcript levels (black bars) were quantified by quantitative polymerase chain 
reaction and expressed relative to control cultures (n = 2), *P < 0.05. Panel III: Cardiomyogenesis was quantified as described 
for Panel II, n = 4. Panel IV: On days 6 and 9 total RNA was harvested for northern blot analysis and probed with the cDNAs 
indicated on the right. Panel V: A time course of P19[BMP4] and P19[control] cells aggregated in the presence of DMSO and 
RA. Total RNA was harvested for northern blot analysis on days 1-4, 6, and 9 and probed with the cDNAs indicated on the 
right.
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cultures (Figure 8, panel VA). Pax3 and MyoD transcripts
were detected in cells treated with RA alone in a similar
expression pattern compared to cultures containing both
RA and BMP4 (Figure 8, panels VB and C, lanes 1-6 com-
pared to 7-12). These results are in contrast to the loss of
Pax3 and MyoD expression shown in the presence of
BMP4 alone (Figure 7). Therefore, the early enhancement
of Pax3 expression by RA treatment still occurs in the pres-
ence of BMP4 (summarized in Table 1).
Discussion
We have examined the mechanism of P19 stem cell differ-
entiation into skeletal muscle in response to RA, Wnt inhi-
bition, and/or BMP4. We show that BMP signalling
inhibits skeletal muscle specification, via the loss of Pax3
and Meox1, while RA enhances this step. Furthermore, RA
can enhance skeletal myogenesis in the presence of BMP4
but not dominant negative β-catenin. RARs bound
directly to RAREs in the upstream and downstream
genomic regions of Meox1, Pax3 and Wnt3a. Both RA and
BMP4 can activate the function of β-catenin in a reporter
assay in aggregated, DMSO-treated, P19 cells. Thus, RA
functions both upstream and downstream of Wnt3a sig-
nalling to enhance skeletal myogenesis. Inhibition by
BMP4 can be bypassed by RA, implying that RA may func-
tion downstream of BMP4 or that BMP4 inhibition occurs
by affecting RA signalling/generation (Figure 9).
In terms of cardiomyogenesis, RA signalling inhibits
GATA-4 expression, resulting in the loss of cardiomyogen-
esis. RA blocks the expression of endogenous BMP4 and
activates the expression of Tob1, which is an inhibitor of
BMP function. The positioning of RA upstream of BMP4
expression and activity explains the ability of exogenous
BMP4 to compensate for the low levels of BMP4 in the
presence of RA, resulting in the enhancement of cardio-
myogenesis (Figure 9).
We have shown previously that β-catenin is sufficient to
induce skeletal myogenesis in P19 cells, by initiating skel-
etal muscle specification [8]. Here we show that RARs
function as a positive regulator of Wnt signalling by bind-
ing directly to Wnt3a regulatory regions, upregulating
Wnt3a transcript levels and activating of β-catenin. In
other systems, such as F9/mouse ES cell differentiation or
dorsal quail forebrain, RA can upregulate antagonists of
the Wnt pathway, restrict Wnt expression, or inhibit β-cat-
enin activity [73-75]. In contrast, RA upregulates the
expression of Wnts during adult murine neurogenesis, or
vertebrate limb induction [76,77]. Our observed activa-
tion of β-catenin by RA did not appear to involve synergis-
tic interactions between RARs and β-catenin on a β-
catenin-responsive promoter (data not shown). However,
we have not ruled out that, once upregulated by RA signal-
ling,  β-catenin might synergize with RARs to activate
RARE-responsive promoters, as described previously [78].
Interestingly, BMP4 treatment also resulted in the activa-
tion of the β-catenin-responsive promoter, which is not
surprising given that BMPs and Wnts cooperatively pat-
tern mesoderm [79]. It is likely that both RA and BMP4 act
via canonical Wnt signalling to regulate both shared and
distinct target genes, which change over time, dependent
on combinatorial factors.
Pax3 expression is sufficient to initiate skeletal myogene-
sis in aggregated P19 cells [10] and it plays an important
role in embryonic myogenesis [80]. RA accelerated Pax3
expression in P19 cells, likely by activating RARs bound
directly to Pax3 regulatory sequences. Although Pax3
expression was not abrogated by the presence of β-Cat/
EnR, and thus likely not bound by β-Cat/EnR, its expres-
sion alone was not sufficient to initiate skeletal myogene-
sis under these conditions. In contrast, although Meox1 is
also a direct target of RARs, it was not upregulated in the
presence of β-Cat/EnR which implies that β-Cat/EnR may
have bound directly to the Meox1 regulatory sequences
and inhibited its activation by RARs. Future studies will
include a global analysis of RAR and β-catenin binding
sites. The finding that RA cannot bypass the β-Cat/EnR
inhibition implies that β-catenin and RARs bind to an
overlapping, essential set of genes during myogenesis.
Model of the intersection of retinoic acid (RA), Wnt, and  BMP4 signalling during cardiac and skeletal muscle develop- ment Figure 9
Model of the intersection of retinoic acid (RA), Wnt, 
and BMP4 signalling during cardiac and skeletal mus-
cle development. BMP4 upregulates Wnt/β-catenin during 
mesoderm induction (green arrow) and blocks skeletal myo-
genesis by downregulation of Meox1, Pax3 and myogenic 
regulatory factor expression (red inhibition arrow). This inhi-
bition can be reversed by RA, which enhances Tob1, Wnt3a, 
Pax3 and Meox1 expression, activates β-catenin and inhibits 
BMP4 expression (green arrows). RA receptors bind directly 
to the Wnt3a, Meox1, and Pax3 regulatory regions (bold 
green arrows). RA inhibits GATA-4 expression and cardio-
myogenesis, likely by inhibiting BMP4 expression and func-
tion. Grey arrows indicate previous work [references [6,8-
10,35,38,40,44,102,103].
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BMP4 inhibits skeletal myogenesis in vitro and  in vivo
[3,31,35,81]. In agreement with these studies, we show
that BMP4 can inhibit the specification of P19 cells into
the skeletal muscle lineage, shown by the loss of Pax3 and
Meox1 expression. When combined, RA signalling was
able to reverse the inhibition of Pax3 expression by BMP4.
RA signalling enhances the expression of Tob-1, which is
an inhibitor of BMP signalling. However, it is unlikely
that RA functions solely by inhibiting BMP activity. For
example, P19 cells expressing the BMP inhibitor noggin
[44] did not show an enhancement/acceleration of skele-
tal myogenesis (M Jamali and I S Skerjanc, unpublished
observations). Since RA can activate myogenic progenitor
genes in the presence of BMP4, it likely functions to acti-
vate transcription downstream of the BMP inhibitory sig-
nal.
Low levels of RA inhibit cardiomyogenesis in P19 cells
[16], although the mechanism has not been fully charac-
terized. Here we show that RA inhibits the expression of
GATA-4, preventing mesodermal cells from becoming
committed to the cardiac muscle lineage. These results are
similar to the finding that continued exposure to RA dis-
rupts heart formation in Xenopus and zebrafish, although
early in mesodermal patterning RA may increase the pro-
portion of cardiac progenitors [49,53,82]. Low levels of
RA may be redirecting pre-cardiac mesodermal cells into
pre-skeletal mesoderm in P19 cells. Furthermore, RA may
inhibit cardiomyogenesis via downregulation of BMP4
expression and upregulation of the BMP inhibitor Tob1.
BMP4 functions to enhance cardiomyogenesis and can
activate Nkx2-5 and GATA-4 expression [83]. The finding
that exogenous BMP4 can override the inhibition of cardi-
omyogenesis by RA suggests that BMP4 functions down-
stream of the RA inhibition, or that BMP4 reduces the
ability of RA to signal in cardiac muscle precursors.
In P19 and P19CL6 cells, noggin inhibits cardiomyogene-
sis, indicating that BMP signalling is essential [40,44].
However, we found that BMP4 overexpression was not
sufficient to induce cardiomyogenesis in aggregated P19
cells without DMSO treatment, although a mild upregula-
tion of cardiomyogenesis was observed with DMSO.
Indeed, BMP4 during the aggregation stage may be inhib-
itory to cardiomyogenesis [84]. These results contrast with
the role of sonic hedgehog (shh), which is sufficient to
induce cardiomyogenesis in aggregated P19 cells without
DMSO [85]. Shh may provide an earlier signal than BMP4
in the cascade of events leading to cardiomyogenesis.
In other systems BMP and RA have also been shown to
function antagonistically. For example, noggin enhanced
RA function in chick chondrocyte maturation [86]. In
contrast, RA induced the expression of BMP-signalling
molecules and enhances BMP effects in chondrocytes
[87,88]. RA can induce or inhibit BMP expression,
depending on the context [62,89,90]. Finally, BMP2/4 can
inhibit RA-induced neurogenesis in P19 monolayer cul-
tures [91]. Given the high degree of complexity of these
signalling pathways, further studies are required to delin-
eate the cross-talk mechanisms involved.
Conclusion
In conclusion, we have examined the roles of RA, BMP4
and canonical Wnt signalling in directing entry into the
cardiac and skeletal muscle lineages. RA enhanced skeletal
myogenesis by inhibiting BMP4 expression and function,
while activating the expression of pre-skeletal mesoderm
genes, and activating Wnt/β-Catenin signalling. RA inhib-
ited cardiomyogenesis, likely by inhibition of BMP4 func-
tion. RA and BMP4 can each reverse the other's inhibition
of myogenesis. Therefore, the precise balance of these sig-
nalling molecules is necessary to regulate specification
into skeletal or cardiac muscle.
Methods
Plasmid constructs
The expression construct phosphoglycerate kinase (PGK)-
BMP4 contains a 1.8 Kb EcoRI BMP4 cDNA fragment,
containing the complete coding sequence of human
BMP4 (Wyeth Pharmaceuticals, MA, USA), driven by the
pgk-1 promoter. The empty PGK vector was used as con-
trol. The constructs PGK-Puro, B17, and PGK-Lac-Z were
previously described [92].
P19 Cell culture and isolation of stable cell lines
P19 embryonal carcinoma cells (American Type Culture
Collection, VA, USA) were cultured as previously
described [93] in α-minimum essential media supple-
mented with 5% cosmic calf serum (Hyclone, UT, USA)
and 5% fetal bovine serum (Cansera, Rexdale, ON, Can-
ada). P19 [β-cat/EnR] cells were isolated and described
previously [8]. For P19 [BMP4] cells, stable cell lines were
created using similar protocols. Briefly, P19 cells were
transfected with the DNA constructs PGK-BMP4 or the
empty PGK vector along with PGK-puro, PGK-LacZ and
B17 with the aid of the Fugene 6 transfection kit (Roche
Diagnostics Canada, Quebec, Canada) as per manufac-
turer's instructions. Twenty-four hours after transfection,
cells were grown under puromycin selection for 10 days.
Individual colonies were analysed for BMP4 expression.
To examine the role of BMP4 in P19 cell differentiation,
P19 cells, P19 [BMP4] cells, P19 [control] cells, 1:1 mix-
tures of P19 and P19 [BMP4] cells, and 1:1 mixture of P19
and P19 [control] cells were aggregated with or without
0.8-1% DMSO for 4 days in petri dishes [94]. Subse-
quently cells were transferred to tissue culture plates or
gelatin coated cover slips and examined for differentiation
on days 6 or 9.BMC Biology 2009, 7:67 http://www.biomedcentral.com/1741-7007/7/67
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To examine the role of RA in P19 cell differentiation, P19
cells, P19 [β-cat/EnR] cells P19 [BMP4] cells, P19 [con-
trol] cells, 1:1 mixtures of P19 and P19 [BMP4] cells, and
1:1 mixture of P19 and P19 [control] cells were aggregated
with or without 0.8-1% DMSO in the presence of 0-30 nM
all-trans retinoic acid. Stocks of retinoic acid were pur-
chased and prepared every 3-4 months. Each new stock
was titrated for optimal skeletal myogenesis.
Immunofluorescence
For analysis of muscle-specific markers, cultures were
treated as described previously [95] with MF20 [96].
Staining was visualized with a Zeiss Axioskop microscope
and photographed with a Sony 3CCD camera. Images
were formatted using Adobe Photoshop and Canvas soft-
ware. Myogenic differentiation was quantified by count-
ing five to 10 fields containing 100-200 cells.
For analysis of neuron-specific markers, cultures were
plated on gelatin-coated coverslips and cultures were fixed
with methanol at -20°C. Antigenic analysis was per-
formed using mouse-anti-Tuj1 (Research Diagnostics,
USA) guinea pig anti-DCX (Chemicon, USA) and Hoechst
dye as a nuclear marker. To identify PAX3/7-positive cells,
some cultures were also labeled with goat-anti-PAX3/7
(Invitrogen, Canada). Secondary antibodies were AMCA-
or FITC-conjugated anti-mouse-IgG, Cy3-conjugated anti-
guinea pig-IgG, (Jackson ImmunoResearch Laboratories,
USA) and Alexa-488 conjugated anti-goat IgG (Invitrogen,
Canada) where appropriate. Immunofluorescence was
evaluated using OpenLab Software, version 3.4 (Improvi-
sion, MA, USA) on a Leica DMXRA2 microscope equipped
for epifluorescence. Antigen-positive cells were counted in
three to 10 fields in triplicate samples performed over two
independent experiments and data expressed as a percent-
age of the total cell number (n = 6-10). Counts were per-
formed by two investigators blind as to the treatment
conditions of each field.
Northern blot analysis
Cells were harvested for RNA extraction using the Urea/
lithium chloride method [97] as previously described
[98]. The cDNA fragments used to probe for MLC1/3 and
MyoD [47] and for BMP4, GATA4, Pax3, Meox1, Myo-
genin, BrachyuryT, Wnt5b and 18s have been described
previously [10]. A 1.8 Kb Kpn1/Mlu1 full length human
cDNA fragment was used to probe for Tob1 (GeneBank
Accession Number: BC031406) and a 400 bp HindIII
fragment for mouse RALDH2 (GI Number 31982069).
mES cell culture and differentiation
J1 or D3 mES cells were maintained in 15% fetal bovine
serum in the presence of leukemia inhibitory factor (LIF).
Differentiation was induced by aggregating cells in the
absence of LIF. Cells were aggregated in hanging drops
containing 800 cells for 2 days and in suspension for a fur-
ther 5 days. Aggregates were treated with increasing con-
centrations of retinoic acid from day 2 to day 5 or 7 of
differentiation. On day 7 of differentiation, cells were
plated on tissue culture plates and allowed to differentiate
for a further 13 days. The efficiency of myocyte formation
was enhanced by plating at a high cell density. Experi-
ments were performed at least twice with each cell line
with similar enhancement of skeletal myogenic precur-
sors.
PCR Analysis
For RT-PCR southern analysis, total RNA was harvested
from day 7 mES cells and 0.8 μg was subjected to reverse
transcription (Qiagen, Mississauga, Canada). The result-
ant cDNA was subjected to PCR with primers specific for
Pax3, Gata-4 and β-actin [85,99] and for MyoD and
Meox1 [100] described previously. The PCR product was
hybridized to DNA probes and visualized by autoradiog-
raphy.
For quantitative real-time PCR (Q-PCR) expression analy-
sis of mES cells, total RNA was harvested from differenti-
ating cells using the RNeasy Micro kit (Qiagen,
Mississauga, Canada). RNA harvested from P19 cells
using the urea/lithium chloride extraction was further
purified using the RNeasy Micro kit (Qiagen, Mississauga,
Canada). The resultant cDNAs were used for Q-PCR, using
protocols and primers for Pax3/7, Meox1, MyoD, myo-
genin and GAPDH as described previously [100]. Primers
for β-actin are found in Table 1. mRNA levels were nor-
malized to β-actin or glyceraldehyde-3-phosphate dehy-
drogenase levels for the corresponding day and
subsequently to levels in untreated samples for the corre-
sponding day.
Promoter analysis
P19 cells were transfected with 6 μg of the super8 TOP-
Flash [101] or FOPFlash reporter plasmids (generous gifts
from R Moon), as well as with 2 μg of Renilla Luciferase
(Promega, WI, USA), using Fugene Transfection Reagent
(Roche Applied Sciences, QC, Canada). Cells were either
left in monolayer culture or aggregated in the presence of
1% DMSO, 20 mM LiCl, 1% DMSO with retinoic acid, or
1%DMSO with 50 ng/ml BMP4. Luciferase assays were
conducted using the Dual Luciferase Reporter Assay Sys-
tem from Promega, 24 hours after treatment. Luciferase
activity was normalized to Renilla activity. Data from sam-
ples treated with lithium chloride or RA were normalized
to samples treated with DMSO alone.
Chromatin Immunoprecipitation
Protein was cross-linked to DNA and chromatin was har-
vested as described previously [100] from three 150 mm
dishes of day 2 P19 aggregates, treated with 1% DMSOBMC Biology 2009, 7:67 http://www.biomedcentral.com/1741-7007/7/67
Page 18 of 21
(page number not for citation purposes)
and 10 nM RA. For immunoprecipitation, 2 μg of RAR
antibody (Santa Cruz, CA, USA) or 2 μg of rabbit immu-
noglobulin G antiserum (Chemicon, MA, USA) was incu-
bated with chromatin and the immune complexes were
captured by addition of protein-G sepharose beads, as
described [100]. After RNase A and proteinase K treat-
ments, DNA was purified using Qiagen's PCR Purification
Kit (Qiagen, ON, Canada). Relative enrichment of bind-
ing sites compared to the IgG negative control immuno-
precipitation was analysed using SYBR green real-time
PCR, as described above, using primers listed in Table 2.
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